Topics

Expert Advocates Moving Up Immunotherapy in MSI-H Gastric Cancer

10:37 EST 3 Feb 2020 | OncLive

Modest activity has been observed with anti–PD-1 therapies for patients with gastric, esophageal, and hepatocellular carcinoma in later lines of therapy, but for patients with microsatellite instability–high tumors and other subgroups, treatment with these agents has shown benefit over chemotherapy in the first-line setting, according to recent data.

Original Article: Expert Advocates Moving Up Immunotherapy in MSI-H Gastric Cancer

NEXT ARTICLE

More From BioPortfolio on "Expert Advocates Moving Up Immunotherapy in MSI-H Gastric Cancer"

Quick Search